IL-17-话题@MedSci

#IL-17#

68篇内容 | 3395人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1374441, encodeId=d28b13e444142, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, objectType=article, longId=195839, objectId=0f4c19583900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f4c19583900, replyNumber=0, likeNumber=81, createdTime=2020-06-15, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f4c19583900, moduleTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f4c19583900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374440, encodeId=1d0313e444071, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎, objectType=article, longId=195329, objectId=e84519532957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e84519532957, replyNumber=0, likeNumber=154, createdTime=2020-06-06, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e84519532957, moduleTitle=诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e84519532957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374439, encodeId=38d713e443956, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=欧盟批准诺华的IL-17单抗Cosentyx，用于治疗非放射线轴性脊柱关节炎, objectType=article, longId=193367, objectId=384819336e00, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=384819336e00, replyNumber=0, likeNumber=116, createdTime=2020-05-03, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=384819336e00, moduleTitle=欧盟批准诺华的IL-17单抗Cosentyx，用于治疗非放射线轴性脊柱关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=384819336e00)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374438, encodeId=6cbb13e443831, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=J Periodontal Res：牙周健康和疾病患者中唾液Del-1, IL-17和LFA-1的水平分析, objectType=article, longId=192227, objectId=5c0a19222e50, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c0a19222e50, replyNumber=0, likeNumber=69, createdTime=2020-04-15, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c0a19222e50, moduleTitle=J Periodontal Res：牙周健康和疾病患者中唾液Del-1, IL-17和LFA-1的水平分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c0a19222e50)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374437, encodeId=519313e443781, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=J Hepatology： IL-17在脂肪性肝细胞和巨噬细胞中促进酒精相关性肝病中的肝细胞癌的发生, objectType=article, longId=188602, objectId=0572188602fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0572188602fa, replyNumber=0, likeNumber=75, createdTime=2020-02-24, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0572188602fa, moduleTitle=J Hepatology： IL-17在脂肪性肝细胞和巨噬细胞中促进酒精相关性肝病中的肝细胞癌的发生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0572188602fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374436, encodeId=05dd13e4436e4, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=J Rheumatol：IL-17A和IL-17F在类风湿性关节炎和外周型脊椎关节炎中的表达及功能反应, objectType=article, longId=186528, objectId=ba8f18652830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba8f18652830, replyNumber=0, likeNumber=80, createdTime=2020-01-21, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba8f18652830, moduleTitle=J Rheumatol：IL-17A和IL-17F在类风湿性关节炎和外周型脊椎关节炎中的表达及功能反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba8f18652830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374435, encodeId=96fb13e4435e3, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx, objectType=article, longId=186385, objectId=ced718638553, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ced718638553, replyNumber=0, likeNumber=80, createdTime=2020-01-18, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ced718638553, moduleTitle=头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ced718638553)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374434, encodeId=d95213e44343e, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira, objectType=article, longId=184396, objectId=e1d618439611, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e1d618439611, replyNumber=0, likeNumber=64, createdTime=2019-12-09, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e1d618439611, moduleTitle=头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e1d618439611)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374433, encodeId=916013e443356, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=银屑病关节炎头对头实验中，诺华的IL-17单抗Cosentyx与Humira相比未能实现统计学意义的改善, objectType=article, longId=182337, objectId=c39f18233ed9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c39f18233ed9, replyNumber=0, likeNumber=78, createdTime=2019-11-05, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c39f18233ed9, moduleTitle=银屑病关节炎头对头实验中，诺华的IL-17单抗Cosentyx与Humira相比未能实现统计学意义的改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c39f18233ed9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374432, encodeId=407b13e44325d, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=Clinica Chimica Acta：循环IL-17水平升高与炎症性关节炎和疾病活动相关, objectType=article, longId=181555, objectId=d23e181555b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d23e181555b5, replyNumber=0, likeNumber=93, createdTime=2019-10-20, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d23e181555b5, moduleTitle=Clinica Chimica Acta：循环IL-17水平升高与炎症性关节炎和疾病活动相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d23e181555b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374431, encodeId=d12f13e443184, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功, objectType=article, longId=180601, objectId=697618060195, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=697618060195, replyNumber=0, likeNumber=103, createdTime=2019-10-08, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=697618060195, moduleTitle=诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=697618060195)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374430, encodeId=cafb13e443034, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, objectType=article, longId=180571, objectId=711e1805e121, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=711e1805e121, replyNumber=0, likeNumber=46, createdTime=2019-10-07, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=711e1805e121, moduleTitle=头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=711e1805e121)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374429, encodeId=901213e4429eb, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=礼来的IL-17A单抗Taltz获得FDA批准扩展用于活动性强直性脊柱炎, objectType=article, longId=178241, objectId=2a911e824102, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a911e824102, replyNumber=0, likeNumber=78, createdTime=2019-08-29, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a911e824102, moduleTitle=礼来的IL-17A单抗Taltz获得FDA批准扩展用于活动性强直性脊柱炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a911e824102)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374428, encodeId=b8b113e442805, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效, objectType=article, longId=177388, objectId=8ab51e73889d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8ab51e73889d, replyNumber=0, likeNumber=83, createdTime=2019-08-12, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8ab51e73889d, moduleTitle=Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8ab51e73889d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374427, encodeId=d06313e442701, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=诺华的IL-17A单抗Cosentyx显著改善斑块状银屑病疾病症状, objectType=article, longId=173291, objectId=9eb91e32918d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9eb91e32918d, replyNumber=0, likeNumber=90, createdTime=2019-06-28, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9eb91e32918d, moduleTitle=诺华的IL-17A单抗Cosentyx显著改善斑块状银屑病疾病症状, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9eb91e32918d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374426, encodeId=f35713e4426e9, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=Arthritis Rheumatol：乌司奴单抗降低银屑病关节炎血清CRP、IL-17A和IL-17F水平, objectType=article, longId=166550, objectId=e11f166550e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e11f166550e5, replyNumber=0, likeNumber=63, createdTime=2019-05-23, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e11f166550e5, moduleTitle=Arthritis Rheumatol：乌司奴单抗降低银屑病关节炎血清CRP、IL-17A和IL-17F水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e11f166550e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374425, encodeId=014f13e4425b1, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, objectType=article, longId=164909, objectId=f4ff16490983, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ff16490983, replyNumber=0, likeNumber=78, createdTime=2019-04-25, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ff16490983, moduleTitle=礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4ff16490983)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374424, encodeId=b1ad13e44248b, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=诺华的牛皮癣药物IL-17单抗Cosentyx在国内获批上市, objectType=article, longId=163639, objectId=30a2163639f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30a2163639f7, replyNumber=0, likeNumber=107, createdTime=2019-04-06, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30a2163639f7, moduleTitle=诺华的牛皮癣药物IL-17单抗Cosentyx在国内获批上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30a2163639f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374423, encodeId=15b013e44233f, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=DDS： IL-17A可以通过上皮-间质转化促进肠纤维化的发生和发展, objectType=article, longId=153891, objectId=e74a15389151, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e74a15389151, replyNumber=0, likeNumber=97, createdTime=2018-11-20, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e74a15389151, moduleTitle=DDS： IL-17A可以通过上皮-间质转化促进肠纤维化的发生和发展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e74a15389151)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1374422, encodeId=bdba13e4422af, content=<a href='/topic/show?id=1727963861' target=_blank style='color:#2F92EE;'>#IL-17#</a>, objectTitle=Arthritis Rheumatol：IL-17A抑制可减轻实验性脊柱关节炎的炎症并增加新骨形成, objectType=article, longId=153062, objectId=f5a7153062e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5a7153062e3, replyNumber=0, likeNumber=65, createdTime=2018-11-10, rootId=0, userName=fzwish20000, userId=bcaa382, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5a7153062e3, moduleTitle=Arthritis Rheumatol：IL-17A抑制可减轻实验性脊柱关节炎的炎症并增加新骨形成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5a7153062e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

IL-17

2020-05-29

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab

2020-06-15

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

诺华III期PREVENT研究：IL-17A单抗Cosentyx可持久缓解中轴性脊柱关节炎

2020-06-06

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

欧盟批准诺华的IL-17单抗Cosentyx，用于治疗非放射线轴性脊柱关节炎

2020-05-03

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

J Periodontal Res：牙周健康和疾病患者中唾液Del-1, IL-17和LFA-1的水平分析

2020-04-15

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

J Hepatology： IL-17在脂肪性肝细胞和巨噬细胞中促进酒精相关性肝病中的肝细胞癌的发生

2020-02-24

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

J Rheumatol：IL-17A和IL-17F在类风湿性关节炎和外周型脊椎关节炎中的表达及功能反应

2020-01-21

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

头对头牛皮癣临床研究，艾伯维的IL-23单抗Skyrizi显着优于诺华的IL-17单抗Cosentyx

2020-01-18

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

头对头III期牛皮癣研究证实，UCB的IL-17A / IL-17F单抗bimekizumab优于AbbVie的TNF单抗Humira

2019-12-09

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

银屑病关节炎头对头实验中，诺华的IL-17单抗Cosentyx与Humira相比未能实现统计学意义的改善

2019-11-05

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

Clinica Chimica Acta：循环IL-17水平升高与炎症性关节炎和疾病活动相关

2019-10-20

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

诺华的IL-17A单抗Cosentyx治疗非放射线轴性脊柱关节炎的III期临床成功

2019-10-08

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

头对头牛皮癣研究中，礼来的IL-17A单抗Taltz与强生的IL-23单抗Tremfya相比可提高皮肤清除率

2019-10-07

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

礼来的IL-17A单抗Taltz获得FDA批准扩展用于活动性强直性脊柱炎

2019-08-29

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

Lancet发表III期ECLIPSE研究，证明IL-23单抗TREMFYA比IL-17单抗COSENTYX治疗中度至重度银屑病具有更好的长期疗效

2019-08-12

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

诺华的IL-17A单抗Cosentyx显著改善斑块状银屑病疾病症状

2019-06-28

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

Arthritis Rheumatol：乌司奴单抗降低银屑病关节炎血清CRP、IL-17A和IL-17F水平

2019-05-23

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

礼来的IL-17A单抗Taltz治疗非放射性轴向脊柱关节炎，III期临床试验大获成功

2019-04-25

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

诺华的牛皮癣药物IL-17单抗Cosentyx在国内获批上市

2019-04-06

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

DDS： IL-17A可以通过上皮-间质转化促进肠纤维化的发生和发展

2018-11-20

fzwish20000 (审核中...)

前往app查看评论内容

#IL-17#

Arthritis Rheumatol：IL-17A抑制可减轻实验性脊柱关节炎的炎症并增加新骨形成

2018-11-10

科室
- - 订阅+
  - 更多科室
工具
服务